Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders
- 23 July 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 827-840
Abstract
To develop and validate a population pharmacokinetic (PPK) model of oral olanzapine in pediatric Chinese patients in order to individualize therapy in this population. A total of 897 serum concentrations from 269 pediatric patients taking oral olanzapine (ages 8 to 17 years) were collected. Demographic parameters, biological characteristics and concomitant medications were investigated as covariates. The data was analyzed using a nonlinear mixed-effects modeling approach. Bootstrapping (1000 runs), normalized prediction distribution error (NPDE), and external validation of 62 patients were employed. Simulations were performed to explore the individualized dosing regimens in various situations. The one-compartment model with first-order absorption and elimination had an apparent clearance (CL/F) of 10.38 L/h, a distribution volume (V/F) of 9.41 L/kg and an absorption rate constant (Ka) fixed at 0.3 h-1. The equation was CL∕F (L∕h) = 10.38 × (body weight∕60)0.25 ×1.33 (if male) × 0.71 (if co-occurrence of infection) × 0.51 (if co-therapy with fluvoxamine) × 1.27 (if co-therapy with sertraline) × 1.43 (if co-therapy with valproate). The final model had satisfactory stability, robustness, and predictive ability. The results from a simulation suggested the oral olanzapine doses required for male and female pediatric patients weighing between 40-60 kg without co-medication were 10-15 mg/day and 7.5-10 mg/day, respectively, and dosage adjustments should be based on sex and body weight; and co-administrated with valproate, sertraline, or fluvoxamine. This model may help individualize optimum dosing of oral olanzapine for pediatric patients.Keywords
Funding Information
- Beijing Municipal Science & Technology Commission (Z171100001017074)
This publication has 57 references indexed in Scilit:
- Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With SchizophreniaThe Journal of Clinical Pharmacology, 2021
- The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric PatientsEuropean Journal of Drug Metabolism and Pharmacokinetics, 2021
- Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva CocktailClinical Pharmacology & Therapeutics, 2020
- Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta‐review of 78 adverse effectsWorld Psychiatry, 2020
- Quantitative determination of risperidone, paliperidone and olanzapine in human serum by liquid chromatography–tandem mass spectrometry coupled with on‐line solid‐phase extractionBiomedical Chromatography, 2018
- Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysisEuropean Journal of Clinical Pharmacology, 2016
- Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levelsPsychopharmacology, 2015
- Fundamentals of Population Pharmacokinetic ModellingClinical Pharmacokinetics, 2012
- Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of GliclazidePharmaceutical Research, 2006
- Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialPsychopharmacology, 1996